Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

monoclonal antibody "LEQEMBI®" (lecanemab) for the treatment of early Alzheimer's disease (AD)*. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ ...

STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils ... including the establishment of a Patient Assistance Program, to deliver lecanemab to patients awaiting the treatment, aiming to ...

Viehbacher, "Biogen") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aß) ...

The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been ...